Valproic acid capsule delayed release contraindications: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Valproic acid}} {{CMG}} ==Title== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STAVZOR (VALPROIC ACID) CAPSULE, DELAYED RELEASE ..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
Stavzor should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder[see Warnings and Precautions (5.1)]. | |||
Stavzor is contraindicated in patients with known hypersensitivity to the drug. [see Warnings and Precautions (5.11)]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STAVZOR (VALPROIC ACID) CAPSULE, DELAYED RELEASE STAVZOR ( VALPROIC ACID) CAPSULE, DELAYED RELEASE [NOVEN THERAPEUTICS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95a4ddd8-b76a-4128-b2ed-8a36cd5738f9 | publisher = | date = | accessdate = }}</ref> | Stavzor is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.5)]. | ||
Stavzor is contraindicated for use in prophylaxis of migraine headaches in pregnant women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STAVZOR (VALPROIC ACID) CAPSULE, DELAYED RELEASE STAVZOR ( VALPROIC ACID) CAPSULE, DELAYED RELEASE [NOVEN THERAPEUTICS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95a4ddd8-b76a-4128-b2ed-8a36cd5738f9 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 22:42, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Stavzor should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder[see Warnings and Precautions (5.1)].
Stavzor is contraindicated in patients with known hypersensitivity to the drug. [see Warnings and Precautions (5.11)].
Stavzor is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.5)].
Stavzor is contraindicated for use in prophylaxis of migraine headaches in pregnant women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].[1]
References
Adapted from the FDA Package Insert.